Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.46 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956542 | 1.00 | AHR (0.50) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL10300642 | 0.83 | AHR (0.50) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL5134069 | 0.79 | AHR (0.50) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL29955770 | 0.71 | AHR (0.46) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL5850255 | 0.70 | NPC1 (0.79) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL2530865 | 0.69 | GPR84 (0.67) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL12900638 | 0.68 | KDM4E (0.38) | CYP1A2 | |
| SCHEMBL177313 | 0.67 | AHR (0.56) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL74304 | 0.67 | AHR (1.00) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL18805065 | 0.67 | AHR (1.00) | AHRNR4A2CYP2A6F7LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112824438-A | Novel synthesis method of polyimide | 湘潭大学 | 2021-05-21 | — | — | CN | claimed |
| CN-112824438-B | Synthetic method of polyimide | 湘潭大学 | 2022-05-17 | — | — | CN | disclosed |
| CN-112824438-A | Novel synthesis method of polyimide | 湘潭大学 | 2021-05-21 | — | — | CN | disclosed |
| US-9969721-B2 | Process for the preparation of vilazodone hydrochloride and its amorphous form | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2018-05-15 | — | — | US | disclosed |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. | 2018-01-25 | — | — | US | disclosed |
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170306234-A1 | LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170283700-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
| US-20170145312-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9533949-B2 | Processes for the preparation of 3-alkyl indoles | APOTEX PHARMACHEM INC. (CA) | 2017-01-03 | — | — | US | disclosed |
| US-7375219-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-7323608-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-01-29 | — | — | US | disclosed |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| US-20070254940-A1 | 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2007-11-01 | — | — | US | disclosed |
| US-20070105924-A1 | Vigabatrin bioisoteres and related methods of use | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-05-10 | — | — | US | disclosed |
| WO-2007050381-A2 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
| US-20070021493-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| US-20050070578-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | RCC1, CCDC47, ACIN1 | AHR 4159/4885NR4A2 3092/4885CYP2A6 3817/4885 |
| US-20070021493-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | SHH, SMO, GLI1 | AHR 2699/4885NR4A2 2848/4885CYP2A6 4862/4885 |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | HTR6, HTR3B, HTR1B | AHR 1233/4885NR4A2 1229/4885CYP2A6 223/4885 |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | TRPC5, TRPV5, TRPV1 | AHR 198/4885NR4A2 2297/4885CYP2A6 311/4885 |
| US-20070105924-A1 | Vigabatrin bioisoteres and related methods of use | GABRB3, GABRB2, GABRE | AHR 3782/4885NR4A2 2981/4885CYP2A6 194/4885 |
| US-20050070578-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | AHR 611/4885NR4A2 603/4885CYP2A6 4348/4885 |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | OGFRL1, OPRL1, ORMDL3 | AHR 179/4885NR4A2 197/4885CYP2A6 1365/4885 |
| US-20070254940-A1 | 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity | NOS1, NOS3, NOS2 | AHR 2824/4885NR4A2 4256/4885CYP2A6 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.